T Cells and TNF: The Impact of TNF Blockade on Effector T Cell Populations in Rheumatoid Arthritis and Other Conditions Treated With Anti-TNFalpha Agents

Trial Profile

T Cells and TNF: The Impact of TNF Blockade on Effector T Cell Populations in Rheumatoid Arthritis and Other Conditions Treated With Anti-TNFalpha Agents

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs Adalimumab (Primary) ; Etanercept (Primary)
  • Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 16 Mar 2012 Planned end date (26 Nov 2012) as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top